Sunday, February 14, 2021 11:35:16 AM
I was somewhat shocked by the monthly cost of $553/month
https://www.goodrx.com/xiidra
I was also curious about how tough it will be to capture market share and, based on the reviews, it looks like that will be fairly easy.
"Xiidra has an average rating of 3.9 out of 10 from a total of 180 ratings for the treatment of Dry Eye Disease. 22% of those users who reviewed Xiidra reported a positive effect, while 58% reported a negative effect"
https://www.drugs.com/comments/lifitegrast-ophthalmic/xiidra-for-dry-eye-disease.html?page=2#:~:text=Xiidra%20has%20an%20average%20rating,58%25%20reported%20a%20negative%20effect.
Seems expensive for those results but anyway I plugged in the following numbers.
30 million affected with dry eye. 1% = 300,000
300,000 x $500/month x 12 = $1.8 B annually
$1.8 B x 0.15 (net margins) = $270,000,000 net
It certainly looks like there is substantial opportunity to bring a new, more effective treatment onto the market. The revenue projections are highly speculative. Time will tell. I cannot find Xiidera revenue in the Novartis annual report since it was recently launched. Probably pretty low. I would guess it'll take 5 years to get the MD's to prescribe anything close to the $270 M number. So start with $50 M net annually as a guesstimate.
$50 M per year net and 37 M shares = $1.35 earnings per share
PE of 20 gets the share price to $27. Lots of variables and moving parts but I like these numbers. I was surprised how close they are to what the analysts provide.
Recent ALDX News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 08:15:22 PM
- Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 09/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 01:02:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:24:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:24:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 10:07:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 09:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:06:48 AM
- Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap • Business Wire • 08/08/2024 11:00:00 AM
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap • Business Wire • 08/07/2024 08:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/01/2024 09:01:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:11:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:03:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 11:01:40 AM
- Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable • Business Wire • 06/20/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 11:01:34 AM
- Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease • Business Wire • 06/13/2024 11:00:00 AM
- Aldeyra Therapeutics to Host Investor Roundtable Q&A • Business Wire • 06/12/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:07:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:09 PM
- Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 11:00:00 AM
- Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease • Business Wire • 05/08/2024 11:00:00 AM
- Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day • Business Wire • 04/25/2024 11:00:00 AM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM